Replies to post #57 on Pharmasset Inc. (fka VRUS)

[surf1944]

6:52AM Pharmasset initiates Phase 2b clinical trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3 (VRUS) 24.75 : Co initiates Phase 2b clinical trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3. The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.